With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their ...

GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

About The Study: Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, with generic tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) being the most frequently prescribed medication ...

for HIV prevention, also called pre-exposure prophylaxis (PrEP). These companies will market the low-cost versions of lenacapavir, if approved, in 120 primarily low-and-lower-middle-income countries.

Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...

or PrEP. The results generated considerable excitement since a daily pill is nearly 100% effective but compliance is spotty and there is a stigma attached to regularly taking a drug for HIV.

Early on, human immunodeficiency virus (HIV) causes flu-like symptoms, which are similar across sexes. HIV symptoms in women may differ after the initial infection and include changes in menstrual ...